Colorectal Carcinoma
Conditions
Keywords
Colonoscopy, Mucosal Exposure Device, Artificial Intelligence
Brief summary
N = 264 patients (50% female) aged 75 years and above undergoing colonoscopy were enrolled. Patients were randomly assigned into one of the three intervention groups: the primary intervention arm (CADe in combination with the MED), the second group with MED alone, and the control group with WLE. All detected lesions were removed and sent to histopathology for diagnosis. The primary outcome was the adenoma detection rate. Secondary outcomes were adenoma detection in the left colon in our cohort of patients.
Detailed description
264 patients, with an equal gender distribution (50% female), aged 75 years and above, undergoing screening and diagnostic colonoscopy at The Surgery and Endoscopy Center of Sebring, Sebring, Florida, were enrolled in this study. The eligibility criteria for a randomized controlled trial (RCT) comparing AI and mucosal exposure devices together, mucosal exposure devices alone, and white light endoscopy in patients 75 years and older could be structured as follows. Patients were randomly allocated into one of three study groups: the primary intervention arm, where colonoscopy was performed using the CADe in combination with the MED; the second group underwent colonoscopy solely with the MED, while the control group underwent colonoscopy solely with the WLE. We used a Convolutional Neural Network-based CADe system, GI Genius, acquired for licensed use from Medtronic Inc., Minneapolis, MN. The MED employed was the EndoCuff Vision (ECV) developed by Olympus America, Center Valley, PA, which constitutes part of the standard equipment available. All detected lesions were identified and excised throughout the colonoscopy procedures, and specimens were promptly sent for histopathological analysis. The primary outcome of interest was adenoma detection rate (ADR), defined as the percentage of patients in whom at least one histologically proven adenoma or carcinoma was identified during colonoscopy. Secondary outcomes included ADR in the left colon in our cohort of patients. This study was conducted according to accepted ethical principles and approved by the institutional review board (IRB) of The Surgery and Endoscopy Center of Sebring." Informed consent was obtained from all participants before enrollment, and measures were taken to ensure patient confidentiality and data protection throughout the study period.
Interventions
DEVICEArtificial Intelligence
Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
DEVICEMucosal Exposure Device
The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding "fingers" that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
Sponsors
Pankaj Patel
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Patients were randomly allocated into one of three study groups: the primary intervention arm, where colonoscopy was performed using the CADe in combination with the MED; the second group underwent colonoscopy solely with the MED, while the control group underwent colonoscopy solely with the WLE. Randomization was executed by a scheduler responsible for patient appointments at the practice, ensuring impartial allocation, with the investigators maintaining no involvement in subject assignment to study arms. We used a Convolutional Neural Network-based CADe system, GI Genius, acquired for licensed use from Medtronic Inc., Minneapolis, MN. The MED employed was the EndoCuff Vision (ECV) developed by Olympus America, Center Valley, PA, which constitutes part of the standard equipment available. All detected lesions were identified and excised throughout the colonoscopy procedures, and specimens were promptly sent for histopathological analysis.
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Patients aged 75 years and older. 2. Patients who were able to provide informed consent or had a legally authorized representative who can consent on their behalf. 3. Patients who were deemed fit for colonoscopy based on a pre-procedure evaluation.
Exclusion criteria
1. Patients with acute gastrointestinal conditions such as active colitis, acute diverticulitis, or bowel obstruction. 2. Patients with a history of major colorectal surgery that might alter normal colon anatomy (e.g., colectomy). 3. Patients with severe comorbid conditions that would contraindicate colonoscopy, such as severe cardiopulmonary disease or advanced liver disease. 4. Patients with uncorrected coagulopathies or those on anticoagulation therapy that cannot be safely managed around the time of the procedure. 5. Patients who are unable to adequately prepare the bowel for colonoscopy. 6. Patients who refuse to participate in the study or have a legally authorized representative who refuses consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome Measure | 181 days | The primary outcome of interest was adenoma detection rate (ADR), defined as the percentage of patients in whom at least one histologically proven adenoma or carcinoma was identified during colonoscopy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Outcome Measure | 181 days | Secondary outcomes included Adenoam Detection Rate in the left colon in our cohort of patients. |
Countries
United States
Outcome results
None listed